Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.36M Sell
26,144
-334
-1% -$39.1K 0.23% 102
2026
Q1
$2.92M Buy
26,478
+2,159
+9% +$249K 0.23% 102
2025
Q4
$2.56M Buy
24,319
+2,148
+10% +$202K 0.22% 107
2025
Q3
$1.86M Buy
22,171
+15,327
+224% +$1.26M 0.17% 132
2025
Q2
$542K Sell
6,844
-2,411
-26% -$192K 0.05% 252
2025
Q1
$831K Sell
9,255
-2,675
-22% -$250K 0.09% 202
2024
Q4
$1.19M Sell
11,930
-10,779
-47% -$1.11M 0.13% 170
2024
Q3
$2.58M Sell
22,709
-642
-3% -$76.3K 0.33% 77
2024
Q2
$2.89M Buy
23,351
+228
+1% +$29.4K 0.39% 68
2024
Q1
$3.05M Buy
23,123
+2,595
+13% +$320K 0.42% 62
2023
Q4
$2.24M Sell
20,528
-2,845
-12% -$295K 0.34% 81
2023
Q3
$2.41M Sell
23,373
-609
-3% -$65.6K 0.36% 78
2023
Q2
$2.77M Buy
23,982
+331
+1% +$37.6K 0.41% 70
2023
Q1
$2.52M Buy
+23,651
New +$2.55M 0.39% 67

Other funds holding MRK

Nilsine Partners's MRK Position: Q2 2026 in Review

Nilsine Partners reduced its Merck (MRK) stake by 1.3% in Q2 2026, selling an estimated $39.1K and leaving 26,144 shares worth $3.36M. The position accounts for 0.23% of the portfolio, ranked #102.

Nilsine Partners first reported a position in MRK in Q1 2023 and has held it in 14 quarters since. 1,299 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Nilsine Partners held 26,144 shares of Merck worth $3.36M as of Q2 2026.
  • Nilsine Partners sold 334 Merck shares in Q2 2026, an estimated $39.1K.
  • Merck made up 0.23% of Nilsine Partners's portfolio in Q2 2026, its #102 holding.
  • Nilsine Partners first reported a position in Merck in Q1 2023 and has held it in 14 quarters since.
  • 1,299 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Nilsine Partners's 13F filing for Q2 2026, filed 24 Jul 2026.